Metagenomi adds Eric Bjerkholt to board; board size increases to six

Metagenomi Therapeutics, Inc.

Eric Bjerkholt appointed as Class II director effective Jan 27, 2025; board expands from five to six.
Bjerkholt is CFO of Mirum Pharmaceuticals; previously CFO at Chinook, Aimmune, Sunesis.
He will serve on Audit and Compensation Committees; receives initial option grant of 42,000 shares vesting over 3 years.
Company updated investor deck for J.P. Morgan Healthcare Conference; no specific pipeline details disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Bjerkholt

Class II Director

MGX · Metagenomi Therapeutics, Inc.

Effective: 2025-01-27
Filed: January 16, 2025, 6:59 PM ET

appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Bjerkholt was appointed as Class II Director at Metagenomi Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed Eric Bjerkholt to serve as a director of the Board, each effective as of January 27, 2025

View on SEC.gov

Metagenomi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-006028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.